Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anchor Therapeutics has signed a collaborative agreement with Kyowa Hakko Kirin (KHK) to advance KHK's internal G protein-coupled receptor (GPCR) drug discovery portfolio.
Subscribe to our email newsletter
The collaboration leverages Anchor’s proprietary pepducin technology which provides an approach to studying the in vitro and in vivo biology of GPCRs and screening for small molecule modulators of the targets.
Anchor Therapeutics research and development interim president and senior vice president Thomas McMurry said the agreement will provide KHK with a unique perspective to better evaluate their GPCR targets and advance their internal drug discovery efforts.
"The licensing of pepducin technology as a research tool is a fundamental component of our business strategy, and we are actively pursuing other collaborations with pharmaceutical and biotechnology companies and research institutions," McMurry added.
According to the agreement, Anchor and KHK will work to discover and optimize pepducin research tools to advance the molecular understanding of certain GPCR targets in the KHK portfolio.
KHK will be responsible for application of the research tools against the targets while Anchor will receive an upfront payment, research funding, and downstream milestones.